On the mechanism of drug-induced acceleration of phospholipid translocation in the human erythrocyte membrane.
Small amphiphilic compounds (M(r)<200 Da) such as anaesthetics and hexane derivatives with different polar groups produced a concentration-dependent acceleration of the slow passive transbilayer movement of NBD-labelled phosphatidylcholine in the human erythrocyte membrane. Above a threshold concentration characteristic for each compound, the flip rate gradually increased at increasing concentrations in the medium. For compound concentrations required to produce a defined flip acceleration, corresponding membrane concentrations were estimated using reported octanol/water partition coefficients. The effective threshold membrane concentrations (50-150 mmol l(-1)) varied in the order: hexylamine>isoflurane=hexanoic acid>hexanol=chloroform>hexanethiol=1,1,2,2-tetrachloroethane>chlorohexane. Apolar hexane, which mainly distributes in the apolar membrane core, was much less effective and supersaturating concentrations were required to enhance flip. Localization of the drug at the lipid-water interface seems to be required for flip acceleration. Such a localization may increase the lateral pressure in this region and the bilayer curvature stress with concomitant decrease of order and rigidity at the interface. This unspecific bilayer perturbation is proposed to enhance the probability of formation of hydrophobic defects in the bilayer, facilitating penetration of the polar head group of the phospholipid into the apolar membrane core.
Bootsveld
Andreas
A
Institut für Physiologie,Universitätsklinikum, Aachen, Germany.
Degenhardt
Rosi
R
Kamp
Dietrun
D
Haest
Cees W M
CW
D009327:4-Chloro-7-nitrobenzofurazan / Q000031:analogs & derivatives* / Q000378:metabolism; D018681:Anesthetics, General / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects / Q000502:physiology; D002725:Chloroform / Q000494:pharmacology; D004910:Erythrocyte Membrane / Q000187:drug effects* / Q000378:metabolism*; D006586:Hexanes / Q000494:pharmacology; D006801:Humans; D007530:Isoflurane / Q000494:pharmacology; D010713:Phosphatidylcholines / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*; D013501:Surface-Active Agents / Q000494:pharmacology
C078632:1-acyl-2-(12-((7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)dodecanoyl)phosphatidylcholine; D018681:Anesthetics, General; D006586:Hexanes; D010713:Phosphatidylcholines; D010743:Phospholipids; D013501:Surface-Active Agents; D002725:Chloroform; D007530:Isoflurane; D009327:4-Chloro-7-nitrobenzofurazan